BriaCell Therapeutics (TSE:BCT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BriaCell Therapeutics is set to present updated survival data and key findings from its Phase 2 trial of Bria-IMT™ at the upcoming San Antonio Breast Cancer Symposium. These presentations will highlight the potential expansion of their cancer immunotherapy to patients with central nervous system metastases. The company’s developments showcase a commitment to advancing cancer treatment through innovative research.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
